Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137685

Published: 2020

Journal Articles

Results of a Phase I Trial of Lenalidomide, Rituximab (R 2 ) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

Brian T. Hill, MD, Deepa Jagadeesh, MDMPH, Alex V. Mejia Garcia, MD, Robert M. Dean, MD, Omer N. Koc, MD, Matt Kalaycio, MD, Kirsten M Boughan, DO, Brenda W. Cooper, MD, Allison M. Winter, MD, Wesam B. Ahmed, MD, Brad Pohlman, MD, Christopher D'Andrea, PA-C, Kelsey Holkovic, RN, Ashley Morrison, RN, Paolo Caimi, MD, Mitchell Smith, MDPhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136370

Published: 2020

Journal Articles

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Naveed Ali, MD, Ana Carolina Pires de Rezende, MD, Folashade Otegbeye, MBBChir,MPH, Mariana Nassif Kerbauy, MD, Brenda W. Cooper, MD, David Mansur, MD, Gisele Pereira, PhD, Roberto Sakuraba, MD, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Cinthya Correa Silva, MD, Leland Metheny, III, MD, Andreza Feitosa Ribeiro, MD, Molly M Gallogly, MDPhD, Ehsan Malek, MD, EDuardo Weltman, MD, Marcos de Lima, MD, Nelson Hamerschlak, MD PhD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142197

Published: 2020

Journal Articles

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Anna Eversman, Shufen Cao, Kirsten M Boughan, DO, Molly M Gallogly, MDPhD, Ehsan Malek, MD, Leland Metheny, III, MD, Timothy E. O'Brien, MD, Folashade Otegbeye, MBBChir,MPH, Brenda W. Cooper, MD, Pingfu Fu, Marcos de Lima, MD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140042

Published: 2020

Journal Articles

Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Ehsan Malek, MD, Jeries Kort, MD, Gi-Ming Wang, PhD, Paolo F Caimi, MD, Kirsten M Boughan, DO, Stanton L. Gerson, MD, Brenda W. Cooper, MD, Molly M Gallogly, MDPhD, Benjamin K. Tomlinson, MD, Marcos de Lima, MD, Curtis Tatsuoka, PhD, James Driscoll

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-139733

Published: 2020

Journal Articles

Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Keith Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark J. Levis, MD, Tara L. Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, Chaofeng Liu, PhD MBA, Erkut Bahceci, MD

Blood (2017) 130 (Supplement 1): 722.

https://doi.org/10.1182/blood.V130.Suppl_1.722.722

Published: 2017

Journal Articles

Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect

Ehsan Malek, MD, Richard Creger, PhD, Merle Kolk, Fahrettin Covut, MD, Richard E Champlin, MD, Brenda W. Cooper, MD, Paolo Caimi, MD, Hillard M Lazarus, MD, Vinita Gupta, MD, Anant Vatsayan, MD MBBS, Qaiser Bashir, MD MBBS, Marcos De Lima, MD, Muzaffar H. Qazilbash, MD

Blood (2017) 130 (Supplement 1): 680.

https://doi.org/10.1182/blood.V130.Suppl_1.680.680

Published: 2017

Journal Articles

Effect of Histologic Grade on Clinical Outcomes of Follicular Lymphoma: Prolonged Progression Free Survival of Grade 3 Follicular Lymphoma in the Rituximab Era

Suchitra Sundaram, MBBS, Erika Moore, MD, Sabarish Ayyappan, MBBS, Fahrettin Covut, MD, Benjamin Tomlinson, MD, Richard Creger, PhD, Ehsan Malek, MD, Leland Metheny, MD, Brenda W. Cooper, MD, Hillard M Lazarus, MD, Marcos de Lima, MD, Paolo Caimi, MD

Blood (2017) 130 (Supplement 1): 2775.

https://doi.org/10.1182/blood.V130.Suppl_1.2775.2775

Published: 2017

Journal Articles

Early Cardiovascular Toxicity with Treatment of Follicular Lymphoma Is Associated with Shorter Overall Survival

Suchitra Sundaram, MBBS, Gouri Dharmavaram, Benjamin K. Tomlinson, MD, Richard Creger, PhD, Ehsan Malek, MD, Leland Metheny, MD, Brenda W. Cooper, MD, Hillard M Lazarus, MD, Marcos de Lima, MD, Paolo Caimi, MD

Blood (2017) 130 (Supplement 1): 2776.

https://doi.org/10.1182/blood.V130.Suppl_1.2776.2776

Published: 2017

Journal Articles

Central Nervous System Relapse in Diffuse Large B Cell Lymphoma—Predictors at Diagnosis

Sabarish Ayyappan, MBBS, Fahrettin Covut, MD, Dhivya Prabhakar, MD, Vinita Gupta, MD, Ehsan Malek, MD, Leland Metheny, MD, Ben K. Tomlinson, MD, Richard Creger, PhD, Brenda W. Cooper, MD, Hillard M Lazarus, MD, Marcos de Lima, MD, Paolo Caimi, MD

Blood (2017) 130 (Supplement 1): 2842.

https://doi.org/10.1182/blood.V130.Suppl_1.2842.2842

Published: 2017

Journal Articles

Treatment of Secondary Post-Transplant Engraftment Failure with Donor CD34+ Enriched, T-Cell Depleted Peripheral Blood Stem Cells Isolated By the Clinimacs® System

Paolo Caimi, MD, Jane Reese, Merle Kolk, Robert Fox, Kari Eckmeyer, RN, Erin Galloway, RN BSN, Gina Hoffman, Ehsan Malek, MD, Leland Metheny, MD, Ben K. Tomlinson, MD, Richard Creger, PhD, Brenda W. Cooper, MD, Hillard M Lazarus, MD, Marcos de Lima, MD

Blood (2017) 130 (Supplement 1): 1956.

https://doi.org/10.1182/blood.V130.Suppl_1.1956.1956

Published: 2017

Journal Articles

A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results

Blood (2017) 130 (Supplement 1): 150.

https://doi.org/10.1182/blood.V130.Suppl_1.150.150

Published: 2017

Journal Articles

Optimizing Autologous Stem Cell Transplant for High-Risk Patients with Plasma Cell Dyscrasias

Naveed Ali, MD, Brenda W. Cooper, MD, Merle Kolk, Richard Creger, PhD, Gina Hoffman, Hillard M Lazarus, MD, Ben K. Tomlinson, MD, Paolo Caimi, MD, Leland Metheny, MD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2017) 130 (Supplement 1): 5656.

https://doi.org/10.1182/blood.V130.Suppl_1.5656.5656

Published: 2017

Journal Articles

Prognostic Impact of Morphological Cellularity in Early Assessment Bone Marrow Biopsy after 7+3 Induction in Patients with Acute Myeloid Leukemia

Fahrettin Covut, MD, Divya Gupta, MD, Raisa Pinto, MD, Nina Dambrosio, CNP, Najla H El Jurdi, MD, Masumi Ueda, MD MA, BA, Leland Metheny, MD, Brenda W. Cooper, MD, Paolo Caimi, MD, Ehsan Malek, MD, Folashade Otegbeye, MBBChir, MPH, Marcos De Lima, MD, Ben K. Tomlinson, MD

Blood (2017) 130 (Supplement 1): 1314.

https://doi.org/10.1182/blood.V130.Suppl_1.1314.1314

Published: 2017

Journal Articles

A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia

Molly M Gallogly, MDPhD, Ben K. Tomlinson, MD, Pam Bunner, MT, CCRC, Paolo Caimi, MD, Michael Craig, MD, Marcos de Lima, MD, Stanton L. Gerson, MD, Donna Kane, RN, MSN, Hillard M Lazarus, MD, Mark J. Levis, MD, Ehsan Malek, MD, Jane A. Little, MD, Crystal Street, MT, CCRC, Willem J. van Heeckeren, MD PhD, William Tse, MD, Brenda W. Cooper, MD

Blood (2017) 130 (Supplement 1): 1332.

https://doi.org/10.1182/blood.V130.Suppl_1.1332.1332

Published: 2017

Journal Articles

Use of a Fitness Tracking Device to Monitor Physical Activity and Sleep Patterns during Hospitalization for Hematopoietic Stem Cell Transplant. Results of a Prospective Observational Study

Najla H El Jurdi, MD, Mathew J Cotton, MS, Raisa Pinto, MD, Erin Galloway, RN BSN, Samantha Kolke, RN, BSN, Brenda W. Cooper, MD, Ben K. Tomlinson, MD, Leland Metheny, MD, Ehsan Malek, MD, Nora Nock, PhD, Merle Kolk, Richard Lee, Marcos De Lima, MD, Paolo Caimi, MD

Blood (2017) 130 (Supplement 1): 3446.

https://doi.org/10.1182/blood.V130.Suppl_1.3446.3446

Published: 2017

Journal Articles

Pilot Use of a Novel DNA Methytransferase -1 (DNMT1) Flow Cytometric Pharmacodynamic Assay to Evaluate Response to Low-Dose Azacitidine Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Hematopoietic Cell Transplantation

Najla H El Jurdi, MD, Masumi Ueda, MD MA, BA, Philip Woost, PhD, Hillard M Lazarus, MD, Paolo Caimi, MD, Brenda W. Cooper, MD, Richard Creger, PhD, Jane A. Little, MD, Linda Baer, MSN, NP-C, AOCNP, Lauren Brister, MSN, NP-C, AOCNP, Ehsan Malek, MD, Leland Metheny, MD, Folashade Otegbeye, MBBChir, MPH, Ben K. Tomlinson, MD, Basem M. William, MRCP,MD, James Jacobberger, PhD, Marcos De Lima, MD

Blood (2017) 130 (Supplement 1): 5503.

https://doi.org/10.1182/blood.V130.Suppl_1.5503.5503

Published: 2017

Journal Articles

Brentuximab Vedotin (BV) Does Not Impair Autologous Peripheral Blood Stem Cell Mobilization and Collection in Refractory/Relapsed CD30+ Lymphoma Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant (HDC-ASCT)

Manuel Afable, BSN, MD, Paolo F. Caimi, MD, Chitra Hosing, Marcos de Lima, MD, Issa F. Khouri, MD, Basem M. William, MD, Yago Nieto, MD PhD, Brenda W. Cooper, MD, Paolo Anderlini, MD, Erica L Campagnaro, MD, Stanton L. Gerson, Hillard M. Lazarus, MD, Richard E. Champlin, Uday R. Popat, MD

Blood (2014) 124 (21): 3854.

https://doi.org/10.1182/blood.V124.21.3854.3854

Published: 2014

Journal Articles

Charlson Comorbidity Index (CCI) and Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) Do Not Predict Transplant Related Mortality (TRM) and Post-Transplant Outcomes In Young Patients Undergoing Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation

Oana V. Paun, MD, Tamila L. Kindwall-Keller, DO, Hillard M. Lazarus, MD, Mary J. Laughlin, MD, Paolo F. Caimi, MD, Merle J. Kolk, Richard J. Creger, Pharm D, Huda Salman, MD, Stanton L. Gerson, MD, Brenda W Cooper, MD

Blood (2013) 122 (21): 4582.

https://doi.org/10.1182/blood.V122.21.4582.4582

Published: 2013

Journal Articles

Second Umbilical Cord Blood Transplant (UCBT2) In Adult Patients With Engraftment Failure Or Autologous Hematopoiesis After UCBT

Paolo F. Caimi, MD, Ronald Sobecks, MD, Pingfu Fu, Ph., D., Brenda W Cooper, MD, Erica L. Campagnaro, MD, Basem M. William, MRCP, MD, Rolla Abu-Arja, MD, Merle J. Kolk, Richard J Creger, Pharm D, Hien Kim Duong, MD, Brian T. Hill, MD, PhD, Brian J. Bolwell, MD, Matt Kalaycio, MD, Marcos de Lima, MD, Hillard M. Lazarus, MD

Blood (2013) 122 (21): 2117.

https://doi.org/10.1182/blood.V122.21.2117.2117

Published: 2013

NARROW

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Results of a Phase I Trial of Lenalidomide, Rituximab (R 2 ) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma

Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect

Effect of Histologic Grade on Clinical Outcomes of Follicular Lymphoma: Prolonged Progression Free Survival of Grade 3 Follicular Lymphoma in the Rituximab Era

Early Cardiovascular Toxicity with Treatment of Follicular Lymphoma Is Associated with Shorter Overall Survival

Central Nervous System Relapse in Diffuse Large B Cell Lymphoma—Predictors at Diagnosis

Treatment of Secondary Post-Transplant Engraftment Failure with Donor CD34+ Enriched, T-Cell Depleted Peripheral Blood Stem Cells Isolated By the Clinimacs® System

A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results

Optimizing Autologous Stem Cell Transplant for High-Risk Patients with Plasma Cell Dyscrasias

Prognostic Impact of Morphological Cellularity in Early Assessment Bone Marrow Biopsy after 7+3 Induction in Patients with Acute Myeloid Leukemia

A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia

Use of a Fitness Tracking Device to Monitor Physical Activity and Sleep Patterns during Hospitalization for Hematopoietic Stem Cell Transplant. Results of a Prospective Observational Study

Pilot Use of a Novel DNA Methytransferase -1 (DNMT1) Flow Cytometric Pharmacodynamic Assay to Evaluate Response to Low-Dose Azacitidine Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Hematopoietic Cell Transplantation

Brentuximab Vedotin (BV) Does Not Impair Autologous Peripheral Blood Stem Cell Mobilization and Collection in Refractory/Relapsed CD30+ Lymphoma Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant (HDC-ASCT)

Charlson Comorbidity Index (CCI) and Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) Do Not Predict Transplant Related Mortality (TRM) and Post-Transplant Outcomes In Young Patients Undergoing Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation

Second Umbilical Cord Blood Transplant (UCBT2) In Adult Patients With Engraftment Failure Or Autologous Hematopoiesis After UCBT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only